Characteristics of the selected vaccines
| Criteria | Ebola virus disease (rVSV-ZEBOV) | Yellow fever (17D) | Meningitis A (MenAfriVac) |
| Cold chain requirements | −70°C | 2°C–8°C72 | 2°C–8°C73 |
| Dose regimen | Single dose | Single dose | Single dose74 |
| Target populations during outbreak-related campaigns | Adults aged ≥18 years* Healthcare workers, contacts of confirmed cases and contacts of contacts | Children and adults† aged ≥9 months72 | Children and adults aged 1–29 years74 |
| Regions | Democratic Republic of Congo, Burundi, Guinea, Liberia, Sierra Leone, Rwanda, Uganda | Africa and South America | ‘Meningitis belt’ in Africa—sub-Saharan Africa from Senegal to Ethiopia73 |
| Year developed/licensed | 201975 | 192772 | 201073 |
| Key similarities with COVID-19 vaccines | Primarily targeted adults; required ultra-cold chain management | Targeted adults as well as children | Targeted adults as well as children |
*Children aged 6–17 years also included in some phase 1–3 trials76; children >6 months were included in the 2018–2020 outbreak in Democratic Republic of Congo under compassionate use protocol.77
†Upper limit age group varied by outbreak.